The global oligonucleotide CDMO market was valued at USD 2.1 billion in 2025 and is projected to reach USD 8 billion by 2032, expanding at a CAGR of 21.05% during the forecast period. Oligonucleotide contract development and manufacturing organizations (CDMOs) provide specialized end-to-end services for the development, process optimization, analytical testing, regulatory support, scale-up, and commercial manufacturing of oligonucleotide-based therapeutics. These include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), guide RNA (gRNA), aptamers, and other emerging nucleic acid modalities. As pharmaceutical and biotechnology companies continue to accelerate the development of RNA-based medicines, demand for highly specialized CDMO partners has increased significantly due to the technical complexity, stringent quality requirements, and capital-intensive nature of oligonucleotide manufacturing. These organizations play a critical role in supporting drug developers from early-stage research through commercial production while ensuring compliance with global GMP standards.

Market expansion is being driven by the rapidly growing pipeline of oligonucleotide therapeutics, increasing outsourcing of development and manufacturing activities, and continuous advances in oligonucleotide synthesis and delivery technologies. Pharmaceutical companies are increasingly relying on experienced CDMOs to reduce development timelines, access specialized manufacturing expertise, and expand production capacity without substantial capital investment. Industry innovation is focused on high-throughput synthesis platforms, continuous manufacturing technologies, GalNAc conjugation, lipid nanoparticle (LNP) delivery systems, automated purification technologies, and commercial-scale GMP production facilities. Strategic investments in manufacturing infrastructure, long-term outsourcing agreements, and collaborations between biotechnology innovators and CDMOs are expected to strengthen the market over the coming years. Growing regulatory approvals for RNA therapeutics and increasing commercialization of precision medicines are also expected to support sustained market growth worldwide.

Key Highlights of the Report

• In terms of service, Contract Manufacturing dominates the global oligonucleotide CDMO market, driven by increasing commercial production requirements for approved and late-stage oligonucleotide therapeutics requiring large-scale GMP manufacturing capabilities.

• The Contract Development segment is projected to witness significant growth as pharmaceutical and biotechnology companies continue expanding early-stage RNA therapeutic pipelines requiring specialized process development and scale-up expertise.

• Based on molecule type, Antisense Oligonucleotides (ASO) account for the largest share of the market due to the growing number of approved therapies and an expanding late-stage clinical pipeline targeting rare genetic, neurological, and metabolic disorders.

• The Small Interfering RNA (siRNA) segment is expected to register rapid growth, supported by increasing clinical success, technological advancements in targeted delivery, and expanding therapeutic applications.

• Pharmaceutical and biotechnology companies continue to increase outsourcing activities to reduce manufacturing complexity, optimize operational costs, and accelerate product commercialization.

• Growing investments in commercial-scale GMP manufacturing facilities remain one of the primary factors supporting long-term market expansion.

• Technological advancements in oligonucleotide synthesis, purification, conjugation chemistry, and analytical characterization continue to improve manufacturing efficiency and product quality.

• Increasing adoption of RNA-based therapeutics for rare diseases, oncology, cardiovascular disorders, neurological diseases, and genetic disorders continues to strengthen long-term market demand.

• Expansion of GalNAc conjugation technologies and lipid nanoparticle delivery platforms is creating new opportunities for advanced oligonucleotide manufacturing.

• High capital investment requirements, specialized production infrastructure, and stringent regulatory compliance continue to represent major challenges for manufacturers entering the market.

• Strategic collaborations between CDMOs and pharmaceutical innovators are accelerating technology transfer, process optimization, and commercial manufacturing capacity expansion.

• By region, North America dominates the global oligonucleotide CDMO market, supported by a well-established biotechnology ecosystem, extensive clinical research activities, advanced manufacturing infrastructure, and the presence of leading CDMO service providers.

• Asia Pacific is projected to be the fastest-growing regional market, driven by expanding biopharmaceutical investments, increasing outsourcing activities, favorable manufacturing economics, and continuous expansion of GMP production capacity.

• The competitive landscape is moderately concentrated, with Agilent Technologies leading the market, while the top five companies collectively account for a significant share of global revenue through continuous capacity expansion, strategic acquisitions, and technology-focused partnerships.

Key Company Profiles

• Agilent Technologies
• Ajinomoto Bio-Pharma Services
• Aurigene Pharmaceutical Services
• Bachem Holding
• CordenPharma
• Eurofins Scientific
• Kaneka Eurogentec
• Thermo Fisher Scientific
• ST Pharm
• TriLink BioTechnologies
• WuXi AppTec
• CPC Scientific

For more details, please visit: https://apeloconsulting.com/product/global-oligonucleotide-cdmo-market-and-forecast-to-2032/

Data Source

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.